NACE Allergy Studies Metadata Platform (NACE)

The National Allergy Centre for Excellence (NACE) - Australia's peak allergy research body hosted at Murdoch Children's Research Institute - has established an initiative to support large scale research and clinical trials in drug, food, insect and respiratory allergies across Australia. In an effort to advance research and foster greater collaboration in the field, the NACE has collated a database of allergy studies to be publicly visible on the LifeCourse platform.

By listing these studies on LifeCourse, we aim to:

  1. Enhance data discoverability by allowing researchers to easily locate and request access to valuable data for their studies;
  2. Facilitate collaboration by encouraging interdisciplinary research through the provision of a shared resource for analysis;
  3. Accelerate discoveries by supporting researchers to build on findings, validate results, and uncover new insights in the field of allergy research.

For detailed information about a specific study, contact the study team directly.

 

Study Summary
Study name NACE Allergy Studies Metadata Platform
Study abbreviation NACE
Current principal investigator/s https://www.nace.org.au/about/our-people
Current project manager

Prof Janet Davies and Prof Kirsten Perrett
Primary Institution/s Murdoch Children’s Research Institute - MCRI
Queensland University of Technology - QUT
Major funding source/s Commonwealth Department of Health and Aged Care
Study website https://www.nace.org.au/allergy-studies-directory/
Study focus

The NACE Allergy Studies Metadata Platform enhances the visibility and accessibility of numerous completed, current and emerging allergy studies. The platform supports researchers to review metadata on allergy studies, to identify opportunities for collaboration and secondary data use through data access request pathways.

Drug studies

Food studies
Sampling frame

Allergy studies across drug, food, insect and respiratory allergic disease that are currently recruiting or underway. Each study has its own defined sampling frame, based on their intended focus.
Primary study type Consortium / Collaboration
Year commenced

2022
Is this study ongoing? Yes - the study is ongoing
Ongoing recruitment? Yes
Sample size (N)

Sample size varies across these studies, please refer to each study for detailed information.
Survey data available? Yes
Imaging data available? No
Linkage to administrative dataset/s? No, no consent to link to administrative dataset(s) obtained
Biosamples available? Yes
Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? Yes
Are there any costs associated with data/sample access for approved requests? There may be costs associated with access, evaluated on a case by case basis
Broadest type of participant consent available Specific consent (can be used for this project only)

2024

Pérez Chacón G, Estcourt MJ, Totterdell J, Marsh JA, Perrett KP, Campbell DE, Wood N, Gold M, Waddington CS, O' Sullivan M, McAlister S, Curtis N, Jones M, McIntyre PB, Holt PG, Richmond PC, Snelling T. (2024). Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial. PLoS Med, 21(6), e1004414. DOI: 10.1371/journal.pmed.1004414

2023

Brettig T, Soriano VX, Dharmage SC, McWilliam V, Peters RL, Perrett K, Koplin JJ. (2023). Cashew Allergy Prevalence and Sensitization in 1-Year-Old Infants. J Allergy Clin Immunol Pract, 11(11), 3478 - 3484.e5. DOI: 10.1016/j.jaip.2023.07.019

De Luca JF, James F, Vogrin S, Chua K, Fletcher L, Nazareth J, Guha R, Hardidge A, Douglas N, Carruthers J, Stewardson A, Cheng AC, Johnson D, Douglass J, Peel T, Trubiano J. (2023). Study protocol for PREPARE: a phase II feasibility/safety randomised controlled trial on PeRiopErative Penicillin AlleRgy TEsting. BMJ Open, 13(2), e067653. DOI: 10.1136/bmjopen-2022-067653

McWilliam VL, Koplin JJ, Allen K, Robinson M, Smart J, Loke P, Peters RL, Dang T, Lee KJ, Dalziel K, Tey D, Taranto M, Perrett KP. (2023). TreEAT trial: Protocol for a randomized controlled trial investigating the efficacy and safety of early introduction of tree nuts for the prevention of tree nut allergy in infants with peanut allergy. Pediatr Allergy Immunol, 34(3), e13930. DOI: 10.1111/pai.13930

O'Sullivan MD, Bear N, Metcalfe J. (2023). Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age. BMJ Paediatr Open, 7(1). DOI: 10.1136/bmjpo-2023-002294

Palmer DJ, Silva DT, Prescott SL. (2023). Feasibility and safety of introducing cashew nut spread in infant diets-A randomized trial. Pediatr Allergy Immunol, 34(6), e13969. DOI: 10.1111/pai.13969

Rose M, Holmes N, Eastwood G, Vogrin S, James F, Phung M, Barnes S, Murfin B, Rogers B, Lambros B, Peel T, Gibney G, Slavin M, Trubiano J. (2023). Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot randomised controlled trial. Pilot Feasibility Stud, 9(1), 126. DOI: 10.1186/s40814-023-01337-8

2022

Copaescu A-M, James F, Vogrin S, Rose M, Chua K, Holmes NE, Turner NA, Stone C, Phillips E, Trubiano J. (2022). Use of a penicillin allergy clinical decision rule to enable direct oral penicillin provocation: an international multicentre randomised control trial in an adult population (PALACE): study protocol. BMJ Open, 12(8), e063784. DOI: 10.1136/bmjopen-2022-063784

James F, Goh MSY, Mouhtouris E, Vogrin S, Chua KYL, Holmes NE, Awad A, Copaescu A-M, De Luca JF, Zubrinich C, Gin D, Cleland H, Douglas A, Kern JS, Katelaris CH, Thien F, Barnes S, Yun J, Tong W, Smith WB, Carr A, Anderson T, Legg A, Bourke J, Mackay LK, Aung AK, Phillips EJ, Trubiano J. (2022). Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR). BMJ Open, 12(8), e055906. DOI: 10.1136/bmjopen-2021-055906

Koplin J, Soriano V, Netting M, Peters R. (2022). Infant feeding patterns before and after changes to food allergy prevention guidelines in Australia. Med J Aust, 217(4), 210 - 211. DOI: 10.5694/mja2.51627

Palmer DJ, Sullivan TR, Campbell DE, Nanan R, Gold MS, Hsu PS, Netting MJ, McWilliam V, Koplin JJ, Perrett KP, Quinn P, O'Sullivan M, Prescott SL, Grivell R, Makrides M. (2022). PrEggNut Study: protocol for a randomised controlled trial investigating the effect of a maternal diet rich in eggs and peanuts from <23 weeks' gestation during pregnancy to 4 months' lactation on infant IgE-mediated egg and peanut allergy outcomes. BMJ Open, 12(6), e056925. DOI: 10.1136/bmjopen-2021-056925

Totterdell JA, Chacon GP, Estcourt MJ, Jones M, Richmond P, Snelling TL, Marsh JA. (2022). Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. Trials, 23(1), 121. DOI: 10.1186/s13063-021-05874-6

2021

Chua KYL, Vogrin S, Bury S, Douglas A, Holmes NE, Tan N, Brusco NK, Hall R, Lambros B, Lean J, Stevenson W, Devchand M, Garrett K, Thursky K, Grayson ML, Slavin MA, Phillips EJ, Trubiano JA. (2021). The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. Clin Infect Dis, 73(3), 487 - 496. DOI: 10.1093/cid/ciaa653

Nakkam N, Gibson A, Mouhtouris E, Konvinse KC, Holmes NE, Chua KY, Deshpande P, Li D, Ostrov DA, Trubiano J, Phillips EJ. (2021). Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. J Allergy Clin Immunol, 147(1), 403 - 405. DOI: 10.1016/j.jaci.2020.04.056

Trubiano J, Marhoon N, Vogrin S, Chua K, Holmes N. (2021). The Long-term Impact of Beta-lactam Antibiotic Allergy Testing - A Matched Case-control Study Journal of Allergy and Clinical Immunology, 147(2), ab15. DOI: 10.1016/j.jaci.2020.12.097

Ying A, Chua KYL, Rose M, Vogrin S, Trubiano JA. (2021). The impact of antibiotic allergy testing in transplant patients. Transpl Infect Dis, 23(1), e13411. DOI: 10.1111/tid.13411

2020

Copaescu A, Rose M, Mouhtouris E, Chua KY, Holmes NE, Phillips EJ, Trubiano JA. (2020). Delayed hypersensitivity associated with amoxicillin-clavulanate. Allergy, 75(10), 2700 - 2702. DOI: 10.1111/all.14359

De Luca JF, Holmes NE, Trubiano JA. (2020). Adverse reactions to vancomycin and cross-reactivity with other antibiotics. Curr Opin Allergy Clin Immunol, 20(4), 352 - 361. DOI: 10.1097/ACI.0000000000000665

Perez Chacon G, Estcourt MJ, Totterdell J, Campbell DE, Perrett KP, Marsh JA, Richmond PC, Wood N, Gold MS, Holt PG, Waddington CS, Snelling TL. (2020). OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. BMJ Open, 10(12), e042838. DOI: 10.1136/bmjopen-2020-042838

Rose MT, Slavin M, Trubiano J. (2020). The democratization of de-labeling: a review of direct oral challenge in adults with low-risk penicillin allergy. Expert Rev Anti Infect Ther, 18(11), 1143 - 1153. DOI: 10.1080/14787210.2020.1792775

Trubiano JA, Chua KYL, Holmes NE, Douglas AP, Mouhtouris E, Goh M, Phillips EJ. (2020). Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. J Allergy Clin Immunol Pract, 8(3), 1142 - 1146.e4. DOI: 10.1016/j.jaip.2019.10.005

Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, Stone CA, Yu R, Groenendijk L, Holmes NE, Phillips EJ. (2020). Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med, 180(5), 745 - 752. DOI: 10.1001/jamainternmed.2020.0403

Wilson A, Trubiano JA, Chua KYL. (2020). Patient perspectives on antibiotic allergy delabeling: Enablers and barriers. J Allergy Clin Immunol Pract, 8(10), 3637 - 3639.e5. DOI: 10.1016/j.jaip.2020.07.017

2018

Ange N, Alley S, Fernando SL, Coyle L, Yun J. (2018). Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract, 6(3), 1059 - 1060. DOI: 10.1016/j.jaip.2017.10.020

Study Contacts
Principal investigator/s https://www.nace.org.au/about/our-people
Project manager

Prof Janet Davies and Prof Kirsten Perrett
Study Contact

Tenaya Jamieson
Email: [email protected]